Spinal and cerebral hematoma in systemic lupus erythematosus and antiphospholipid syndrome: is drug interaction the culprit?
Author:
Duran Emine1ORCID, Bilgin Emre1ORCID, Bölek Ertuğrul Çağrı1, Fırat Oğuzhan2, Bulut Elif3, Kalyoncu Umut1, Kiraz Sedat1, Karadağ Ömer1
Affiliation:
1. Department of Internal Medicine, Division of Rheumatology , Hacettepe University Faculty of Medicine , Ankara , Turkey 2. Department of Clinical Pharmacy , Hacettepe University Faculty of Pharmacy , Ankara , Turkey 3. Department of Radiology , Hacettepe University Faculty of Medicine , Ankara , Turkey
Abstract
Abstract
Objectives
Thrombotic events are common in systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). Warfarin is the most commonly used anticoagulant drug for thrombosis treatment, but it is can interact with many drugs, foods, or medicinal herbs. Herein, we presented a case with SLE and APS who was complicated by spinal and cerebral hematoma as a result of warfarin interaction.
Case presentation
Spinal subdural hematoma and frontal intraparenchymal hematoma were occurred in our patient, who was in remission for 2 years with rituximab, hydroxychloroquine and warfarin. We learned that she had been using some herbal products (shepherd’s purse and horsetail) and phenyramidol for a few days. Spinal and cerebral hematomas caused by the interaction of phenyramidol and warfarin were treated with fresh frozen plasma and vitamin K without the need for surgery.
Conclusions
The drug interactions with warfarin can cause fatal hemorrhagic or thrombotic events. Especially, the patients with SLE and/or APS using warfarin should be warned not to use different medications or herbal agents.
Publisher
Walter de Gruyter GmbH
Subject
Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics
Reference19 articles.
1. Pons-Estel, GJ, Andreoli, L, Scanzi, F, Cervera, R, Tincani, A. The antiphospholipid syndrome in patients with systemic lupus erythematosus. J Autoimmun 2017;76:10–20. https://doi.org/10.1016/j.jaut.2016.10.004. 2. Opatrny, L, David, M, Kahn, SR, Shrier, I, Rey, E. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis. J Rheumatol 2006;33:2214–21. 3. Cervera, R, Serrano, R, Pons-Estel, GJ, Ceberio-Hualde, L, Shoenfeld, Y, de Ramón, E, et al.. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2015;74:1011–8. https://doi.org/10.1136/annrheumdis-2013-204838. 4. Ruiz-Irastorza, G, Cuadrado, M J., Ruiz-Arruza, I, Brey, R, Crowther, M, Derksen, R, et al.. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus 2011;20:206–18. https://doi.org/10.1177/0961203310395803. 5. Bala, MM, Celinska-Lowenhoff, M, Szot, W, Padjas, A, Kaczmarczyk, M, Swierz, MJ, et al.. Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome. Cochrane Database Syst Rev 2017;10:CD012169. https://doi.org/10.1002/14651858.CD012169.pub2.
|
|